KPE 02001003

Drug Profile

KPE 02001003

Alternative Names: KPE02001003; KPE02003002

Latest Information Update: 18 Dec 2008

Price : $50

At a glance

  • Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
  • Developer Kemin Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Dec 2008 No development reported - Phase-II for Hepatitis C in Belgium (unspecified route)
  • 13 Jan 2005 KPE 02001003 is available for licensing worldwide (http://www.kemin.com)
  • 15 Jan 2004 Phase-II clinical trials in Hepatitis C treatment in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top